 Connection
Peter Crooks to Drug Synergism
This is a "connection" page, showing publications Peter Crooks has written about Drug Synergism.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.122 |
|
|
|
-
Lamture G, Crooks PA, Borrelli MJ. Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells. Drug Dev Res. 2018 09; 79(6):287-294.
Score: 0.039
-
Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010 Dec 23; 116(26):5983-90.
Score: 0.023
-
Walsby EJ, Pratt G, Hewamana S, Crooks PA, Burnett AK, Fegan C, Pepper C. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Mol Cancer Ther. 2010 Jun; 9(6):1574-82.
Score: 0.022
-
Smith AM, Pivavarchyk M, Wooters TE, Zhang Z, Zheng G, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochem Pharmacol. 2010 Aug 01; 80(3):402-9.
Score: 0.022
-
Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. J Control Release. 2006 Jun 28; 113(2):137-45.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|